Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Symbolism and naming in spotlight at NSSA conference
2016-10-06

Description: NSSA LN Read More Tags: NSSA LN Read More

From the left, front: Prof Nhlanhla Mathonsi,
President of the NSSA, and Prof Thenjiwe Meyiwa,
Registrar at DUT.
Left, back (from the UFS): Prof Peter Raper,
Research Fellow at the ULFE and executive
member of the scientific council and paper
selection committee, Prof Theodorus du Plessis,
Director of the Unit for Language Facilitation
and Empowerment, and JC van der Merwe,
acting Director of the Institute for
Reconciliation and Social Justice.
Photo: Supplied

The 19th Names Society of Southern Africa (NSSA) International Conference saw delegates from around the world make their way to the University of the Free State (UFS) Bloemfontein Campus to study names as well as naming systems.

The conference took place from 20 to 22 September and was organised by the Unit for Language Facilitation and Empowerment (ULFE) at the UFS, alongside the NSSA. Delegates from South Africa, Lesotho, Zimbabwe, Zambia, Germany, and Taiwan attended.

The NSSA is a society dedicated to the study of names, naming, and naming systems. Members of the society come from a variety of disciplines, but all share an interest in names and their meaning.

Symbolism and naming in public sphere

The topic of this year’s conference was Symbolism and Instrumentality in Naming with categories of research which included anthroponyms, geographical names, names in history, literary onomastics, brand names, and politics of naming in a public sphere.

Issue of gender in naming systems

Keynote speakers included Prof Thenjiwe Meyiwa, Registrar at the Durban University of Technology (DUT), and Prof Peter Raper, Professor Extraordinaire at the UFS, Research Fellow at the ULFE, and executive member of the scientific council and paper selection committee.

In her address entitled, Naming is to gender as gender is to naming: Emerging Onomastics Scholarship, Prof Meyiwa noted that analysing names using gender enquiry is a potentially useful tool for identifying various communities’ values, belief systems, and perceptions as it relates to sexes.

“The talk called for the development of what I refer to as ‘feminist onomastics theory and research practice,’ which should primarily seek to bring about change and/or reimagine onomastics research."

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept